ADR Biomedical Holdings (TSE:3750) Accounts Payable: 円1.65 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:3750 ADR Biomedical Holdings Inc TSE:3750
30 GF Score
Price 円800.00
GF Value 円40.05
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is ADR Biomedical Holdings Accounts Payable?

ADR Biomedical Holdings TSE:3750 30 Accounts Payable is 円1.65 Mil as of Mar. 2026. GuruFocus rates TSE:3750 with a GF Score™ of 30/100 and a GF Value™ of 円40.05 (Significantly Overvalued). The stock has 9 warning signs investors should review.

ADR Biomedical Holdings's Accounts Payable for the quarter that ended in Mar. 2026 was 円1.65 Mil.

ADR Biomedical Holdings's quarterly Accounts Payable declined from Mar. 2025 (円0.28 Mil) to Sep. 2025 (円0.00 Mil) but then increased from Sep. 2025 (円0.00 Mil) to Mar. 2026 (円1.65 Mil).

ADR Biomedical Holdings's annual Accounts Payable increased from Mar. 2024 (円0.00 Mil) to Mar. 2025 (円0.28 Mil) and increased from Mar. 2025 (円0.28 Mil) to Mar. 2026 (円1.65 Mil).

ADR Biomedical Holdings Accounts Payable Related Terms

ADR Biomedical Holdings Accounts Payable Historical Data

* Premium members only.

The historical data trend for ADR Biomedical Holdings's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ADR Biomedical Holdings Accounts Payable Chart

ADR Biomedical Holdings Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.28 1.65

ADR Biomedical Holdings Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.28 0.00 1.65
TSE:3750
30GF Score
ADR Biomedical Holdings Inc TSE:3750
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ADR Biomedical Holdings Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of 円1.65 Mil mean?
ADR Biomedical Holdings (TSE:3750) has a Accounts Payable of 円1.65 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on ADR Biomedical Holdings and its competitors.
Is ADR Biomedical Holdings' Accounts Payable too high?
ADR Biomedical Holdings' current Accounts Payable is 円1.65 Mil. Overall, ADR Biomedical Holdings has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ADR Biomedical Holdings' Accounts Payable compare to VRTX and REGN?
ADR Biomedical Holdings' Accounts Payable of 円1.65 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on ADR Biomedical Holdings and its competitors. ADR Biomedical Holdings's current Accounts Payable is 円1.65 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADR Biomedical Holdings stock overvalued right now?
Based on GuruFocus' analysis, ADR Biomedical Holdings (TSE:3750) is currently considered Significantly Overvalued. The stock's GF Value™ is 円40.05, compared to a current price of 円800.00 — trading 1897.5% above its estimated fair value. The current Accounts Payable is 円1.65 Mil. ADR Biomedical Holdings' overall GF Score™ is 30/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For ADR Biomedical Holdings (TSE:3750), the current Accounts Payable is 円1.65 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ADR Biomedical Holdings (TSE:3750) Overvalued in 2026?

Based on GuruFocus' analysis, ADR Biomedical Holdings stock appears to be overvalued. The current stock price of 円800.00 is trading 1897.5% above its estimated GF Value™ of 円40.05. GuruFocus considers ADR Biomedical Holdings to be Significantly Overvalued.

Key valuation signals for TSE:3750:

  • Accounts Payable: 円1.65 Mil
  • GF Value™: 円40.05 vs. price of 円800.00 (1897.5% above fair value)
  • GF Score™: 30/100 with 9 warning signs

No single metric tells the full story. See the TSE:3750 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ADR Biomedical Holdings Business Description

Address 1-1-1 Otemachi, Otemachi Park Building, Chiyoda-ku, Tokyo, JPN, 100-0004
ADR120S Inc developing a new clinical approach to cell therapy to provide medical care to patients by providing medical care that responds to unmet medical needs based on its regenerative medicine. Its product pipeline includes Habeo; ECCO-50 and others.
30GF Score

Get the complete analysis for TSE:3750

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円800.00
Price
円40.05
GF Value